Wednesday August 5, 2009, 5:00 am EDT
SANTA MONICA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has retired $2.53M of long-term debt.
"The two notes signed in February and March of 2007 respectively, between CBAI and the Shelter Island Opportunity Fund (SIOF), have been retired as of August 3, 2009. With this debt retirement, CBAI has only the put option agreement obligation with SIOF remaining on its balance sheet. Cord Blood America regards this as a key milestone on its path to being able to operate debt free," said Matthew Schissler, Cord Blood America Founder and CEO
read more in the CBAI analyst report
http://bit.ly/VgIy9
Monday, August 10, 2009
Friday, July 17, 2009
Positive market expansion tipping point
Matt Schissler, CEO of Cord Blood America (CBAI.OB) said in an interview with the Wall Street Transcript
“At the University of Florida right now, there is a study going on to see if umbilical cord blood stem cells can treat and cure juvenile diabetes.
“If that does get through trials and end up becoming commercialized, there is a much larger population that has a history of diabetes in the family than they do cancer and leukemia.
“Now you're going to have a much larger population saying, "Okay, this might be a good idea for us to store stem cells" and we believe that's going to be the next tipping point.
“ I think over the next three to ten years you're going to see many new therapies get to market and as those therapies get to market, those therapies are going to affect more and more families and you're going to start seeing a much higher percentage of family storing their stem cells.”
full article:
http://finance.yahoo.com/news/Blood-Stem-Cell-Storage-twst-133935830.html?x=0&.v=2
IPOdesktop CBAI Analyst Report
“At the University of Florida right now, there is a study going on to see if umbilical cord blood stem cells can treat and cure juvenile diabetes.
“If that does get through trials and end up becoming commercialized, there is a much larger population that has a history of diabetes in the family than they do cancer and leukemia.
“Now you're going to have a much larger population saying, "Okay, this might be a good idea for us to store stem cells" and we believe that's going to be the next tipping point.
“ I think over the next three to ten years you're going to see many new therapies get to market and as those therapies get to market, those therapies are going to affect more and more families and you're going to start seeing a much higher percentage of family storing their stem cells.”
full article:
http://finance.yahoo.com/news/Blood-Stem-Cell-Storage-twst-133935830.html?x=0&.v=2
IPOdesktop CBAI Analyst Report
Positive tipping point for umbilical cord blood stem cell storage
Matt Schissler, CEO of Cord Blood America (CBAI.OB” said in an interview with the Wall Street Transcript, July 15, 2009
“At the University of Florida right now, there is a study going on to see if umbilical cord blood stem cells can treat and cure juvenile diabetes.
“If that does get through trials and end up becoming commercialized, there is a much larger population that has a history of diabetes in the family than they do cancer and leukemia.
“Now you're going to have a much larger population saying, "Okay, this might be a good idea for us to store stem cells" and we believe that's going to be the next tipping point.
“ I think over the next three to ten years you're going to see many new therapies get to market and as those therapies get to market, those therapies are going to affect more and more families and you're going to start seeing a much higher percentage of family storing their stem cells.”
IPOdesktop CBAI Analyst Report
“At the University of Florida right now, there is a study going on to see if umbilical cord blood stem cells can treat and cure juvenile diabetes.
“If that does get through trials and end up becoming commercialized, there is a much larger population that has a history of diabetes in the family than they do cancer and leukemia.
“Now you're going to have a much larger population saying, "Okay, this might be a good idea for us to store stem cells" and we believe that's going to be the next tipping point.
“ I think over the next three to ten years you're going to see many new therapies get to market and as those therapies get to market, those therapies are going to affect more and more families and you're going to start seeing a much higher percentage of family storing their stem cells.”
IPOdesktop CBAI Analyst Report
Tuesday, July 7, 2009
$7.5mm capital commitment for Cord Blood America, CBAI
- Cord Blood America secures $7.5 million investment capital commitment from a health care fund
- To be drawn down through the sale of Series A Preferred Stock once a registration statement is filed and declared effective under the Securities Act of 1933
- Use of proceeds
- New stem cell initiatives
- Potential acquisitions
- Working capital needs
http://gaskinsco.com/linkto-cbai.shtml
Wednesday, May 13, 2009
Only one is publicly traded
HIGHLIGHTS
CBAI projects it will become cash flow positive for the first time in its history
OVERVIEW
CBAI projects it will become cash flow positive for the first time in its history
- By continuing to de-lever its balance sheet through debt reductions and
- By expansion through internal growth coupled with strategic acquisitions
OVERVIEW
- Emerging leader in an emerging market
- Umbilical cord blood collection, a non-controversial and valuable source of stem cells
Three cord blood storage industry leaders Viacord, CordBloodAmerica, CordBlood
Three cord blood storage industry leaders Viacord, CordBloodAmerica, CordBlood
read more
http://bit.ly/7tFz9
http://bit.ly/fPUMn
http://bit.ly/Y4bpx
read more
http://bit.ly/7tFz9
http://bit.ly/fPUMn
http://bit.ly/Y4bpx
Cord Blood Used for Type 1 Diabetes Research
“Our primary goal is to study the ability of these cord blood derived cells to modulate a human immune system in a pre-clinical animal model,” said Dale L. Greiner, Ph.D., professor of medicine, University of Massachusetts Mass Medical School.
According to the American Diabetes Association, diabetes is the fifth leading cause of death in the United States. Diabetes affects more than 23.6 million Americans, or 7.8 percent of the population, and is estimated to have a total annual economic cost of $174 billion. Type 1 diabetes, which accounts for between five and ten percent of all diagnosed cases of diabetes, is an autoimmune disease, generally occurring in children and young adults. Because patients with type 1 diabetes do not product insulin naturally, they must have insulin delivered by injection or a pump to help maintain their health. There is no known way to prevent type 1 diabetes.
read more http://bit.ly/YfQeQ
According to the American Diabetes Association, diabetes is the fifth leading cause of death in the United States. Diabetes affects more than 23.6 million Americans, or 7.8 percent of the population, and is estimated to have a total annual economic cost of $174 billion. Type 1 diabetes, which accounts for between five and ten percent of all diagnosed cases of diabetes, is an autoimmune disease, generally occurring in children and young adults. Because patients with type 1 diabetes do not product insulin naturally, they must have insulin delivered by injection or a pump to help maintain their health. There is no known way to prevent type 1 diabetes.
read more http://bit.ly/YfQeQ
Subscribe to:
Posts (Atom)